A. Arana

First name

A.

Last name

Arana

Arana, A., Margulis, A. V., Varas-Lorenzo, C., Bui, C. L., Gilsenan, A., McQuay, L. J., et al. (2020). Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5150

View

Phiri, K., Hallas, J., Linder, M., Margulis, A., Suehs, B., Arana, A., et al. (2021). A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Curr Med Res Opin. http://doi.org/10.1080/03007995.2021.1891035

View

Arana, A., Pottegard, A., Kuiper, J. G., Booth, H., Reutfors, J., Calingaert, B., et al. (2021). Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clinical Epidemiology. http://doi.org/https://doi.org/10.2147/CLEP.S331287

View

Hoffman, V., Hallas, J., Linder, M., Margulis, A. V., Suehs, B. T., Arana, A., et al. (2021). Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-021-01095-7

View